GDLSK

clinical

USTR AMENDS THE SCOPE OF TWO CHINA 301 EXCLUSIONS

The Office of the U.S. Trade Representative (“USTR”) has issued two notices, each amending the scope of an existing China 301 exclusion. In its first notice involving an exclusion issued under China 301 List 1 (the $34 billion trade action), the USTR has amended the exclusion (within U.S. note 20(x)(21) to subchapter III of chapter […]